Cardiovascular health on long-term feminizing HRT¶
The dominant cardiovascular signal in transfeminine HRT is venous thromboembolism in the first year on oral or ethinyl-containing estrogen — not lipid catastrophe, not accelerated atherosclerosis. Arterial event rates rise modestly above cisgender-female baselines but stay below cisgender-male baselines, with the most reproducible elevations in ischemic stroke (and possibly MI) emerging only after several years of follow-up.
Long-term data come mostly from the Amsterdam ENIGI cohort and the Kaiser Permanente Multisite study, both skewing younger than 50 — so outcomes for transfeminine adults aging into their 60s and 70s on continuous HRT are still being filled in. The actionable findings, however, are stable: transdermal 17β-estradiol over oral above age 40 or any risk factor, smoking is the dominant modifiable lever, and lipid trajectories on modern regimens are mostly favorable.
See also: Estrogens, Reference Levels, The 5+ Year Trajectory, Substance Use.
VTE: the one signal that's clearly real¶
VTE is the cardiovascular complication with the strongest, most consistent evidence in transfeminine populations, and it concentrates heavily in the first year. Getahun 2018 (Kaiser, n=2,842, median 4.0 years) found a VTE risk difference of +4.1 per 1,000 at 2 years and +16.7 per 1,000 at 8 years versus matched cisgender men, HR 1.9–2.0. ENIGI (Wiepjes 2018, n=2,627) reported VTE in the first year at roughly 5× the rate seen in subsequent years, with most events clustering in months 0–12.
Mechanism: oral estrogen undergoes first-pass hepatic metabolism, raising procoagulant factors (factor VII, prothrombin fragments) and reducing protein S and antithrombin III. Transdermal 17β-estradiol bypasses the liver and shows minimal hemostatic disturbance.
VTE risk by route and age¶
| Route / formulation | First-year VTE risk vs cis-female baseline | Steady-state (year 2+) | Notes |
|---|---|---|---|
| Transdermal 17β-estradiol | Minimal elevation | Near baseline | Preferred at any age with risk factors |
| Estradiol valerate (oral) | 2–4× elevated | Modest persistent rise | Acceptable in healthy <40 |
| Sublingual / buccal E2 | Intermediate (peak hepatic exposure) | Intermediate | Not equivalent to transdermal |
| Injectable E2 (IM/SQ) | Minimal elevation | Near baseline | Hemostatically like transdermal |
| Ethinyl estradiol (legacy) | 6–20× elevated | Persistent | Eliminated from modern practice |
Long-term excess on a transdermal-dominant or modern-oral regimen is roughly 1–2 additional VTE events per 1,000 person-years above matched cisgender controls — meaningful but not catastrophic, and substantially modifiable by route and smoking. Routine thrombophilia screening is not recommended before HRT initiation; personal or strong family history of unprovoked VTE shifts the calculus toward transdermal.
Oral versus transdermal: the route shift at 40+¶
Most guidelines converge on age 40 as the inflection point, increasingly phrased as "default to transdermal" rather than "consider transdermal." Hembree 2017 recommends transdermal for transfeminine patients over 40 or with any VTE/CVD risk factor; WPATH SOC-8 endorses the same.
Transdermal at therapeutic doses (100–200 µg/day patch, or estradiol gel 2–4 mg/day) achieves identical serum E2 ranges to oral 4–6 mg/day without first-pass hepatic effects.
Route-switch decision matrix¶
| Trigger | Action |
|---|---|
| Age ≥40 | Default transdermal |
| Current smoking | Switch to transdermal |
| BMI ≥30 | Switch to transdermal |
| Hypertension or diabetes | Switch to transdermal |
| Prior VTE (any provocation) | Switch immediately |
| First-degree relative with unprovoked VTE under 50 | Switch to transdermal |
| Known thrombophilia (factor V Leiden, etc.) | Switch to transdermal |
| Migraine with aura | Switch to transdermal |
| Planned major surgery within 6 months | Switch ≥4 weeks pre-op |
| Age 35–40 (no other factors) | Strongly consider transdermal |
| Sedentary occupation, prior superficial thrombophlebitis | Strongly consider transdermal |
| Age <35, healthy non-smoker | Oral estradiol valerate acceptable |
Smoking and estrogen are multiplicative for VTE
The smoking-plus-oral-estrogen combination is approximately multiplicative for VTE risk, and additive-to-multiplicative for arterial events. A transfeminine smoker on oral estradiol who switches to transdermal but continues smoking has done less for cardiovascular risk than one who stays on oral and quits. If only one intervention is going to happen, cessation produces the larger absolute risk reduction. Pharmacotherapy (varenicline, bupropion, NRT) is fully compatible with HRT. See Substance Use.
Lipid trajectory on long-term HRT¶
Estrogen lowers LDL, raises HDL, and modestly raises triglycerides; testosterone suppression contributes to the LDL drop and HDL rise. ENIGI longitudinal data and Maraka 2017 meta-analysis show LDL falling 4–10 mg/dL over the first year, HDL rising 3–8 mg/dL, triglycerides rising 10–20 mg/dL.
The triglyceride rise is route-dependent: oral estrogen drives a larger increase (sometimes 30–50 mg/dL) because hepatic VLDL production is upregulated by first-pass exposure; transdermal produces minimal change. Patients with baseline triglycerides above 250 mg/dL on oral estrogen occasionally see clinically significant elevations and benefit from route switch.
ENIGI 5-year data show LDL remaining below pre-HRT baseline, HDL elevated, total cholesterol mildly reduced, and the LDL:HDL ratio improving by ~10–15%. Apolipoprotein B falls in parallel with LDL-C. Lipoprotein(a) is modestly reduced by oral estrogen and unchanged by transdermal — a small advantage for oral that does not override VTE concerns.
Lipid targets on stable HRT¶
| Marker | Target on stable HRT | Concern threshold |
|---|---|---|
| LDL-C | <100 mg/dL (lower with ASCVD) | ≥190 mg/dL → statin |
| HDL-C | ≥50 mg/dL (typical on E2) | <40 mg/dL → atherogenic risk |
| Triglycerides | <150 mg/dL | ≥250 mg/dL on oral → switch route |
| ≥500 mg/dL → fibrate | ||
| Total cholesterol | <200 mg/dL | ≥240 mg/dL → evaluate |
| Apolipoprotein B | <90 mg/dL | ≥130 mg/dL → high risk |
| Lipoprotein(a) | <50 mg/dL (largely genetic) | ≥50 mg/dL → consider statin earlier |
Lipid improvements on HRT do not necessarily translate to proportionate ASCVD risk reduction. Conventional Framingham/ASCVD calculators are validated against cisgender populations; most clinicians use the cisgender-female calculator for transfeminine patients on stable HRT >5 years and add clinical judgment for residual male-pattern risk factors. See Reference Levels for monitoring cadence.
Statin thresholds¶
Statin indications follow standard ASCVD guidelines, with the qualifier that transfeminine patients are not specifically represented in the underlying RCTs.
| Indication | Recommendation |
|---|---|
| LDL ≥190 mg/dL | Statin regardless of other factors |
| Diabetes + age 40–75 | Statin recommended |
| 10-year ASCVD risk ≥7.5% | Consider statin |
| 10-year ASCVD risk ≥10% | Statin recommended |
| Familial hypercholesterolemia or known ASCVD | High-intensity statin |
| Lp(a) ≥50 mg/dL with other risk factors | Consider statin earlier than calculator |
No evidence statins interact adversely with feminizing HRT. Atorvastatin and rosuvastatin are first-line — minimally affected by CYP3A4 interactions with estrogens. Simvastatin's CYP3A4 dependence makes it slightly less ideal but not contraindicated. Starting a statin does not change HRT calculus, and starting HRT does not delay statin initiation when otherwise indicated.
Blood pressure on long-term HRT¶
Blood pressure changes on feminizing HRT are small in aggregate but variable, with anti-androgen choice as the dominant variable. Spironolactone is mildly antihypertensive (−3 to −6 mmHg systolic), dose-related at 200 mg/day. Cyproterone acetate is approximately neutral. GnRH agonists and bicalutamide are BP-neutral. Estradiol itself has minimal direct BP effect at physiologic replacement doses; older ethinyl-containing regimens raised BP measurably.
Standard hypertension management applies. ACE inhibitors and ARBs are first-line and have no specific HRT interactions. The one specific note: adding a thiazide on top of high-dose spironolactone (≥150 mg/day) requires careful potassium monitoring, and the combination is sometimes a reason to switch the anti-androgen.
Ischemic events: MI and stroke¶
Nota 2019 (ENIGI cardiovascular outcomes, n=2,517, median 9 years) is the most-cited single study.
| Event | vs cisgender women | vs cisgender men |
|---|---|---|
| Ischemic stroke | SIR 2.42 (1.65–3.42) | SIR 1.80 (1.23–2.55) |
| Myocardial infarction | SIR 1.55 (1.07–2.18) | Not different |
| Venous thromboembolism | ~5× higher | ~5× higher |
Absolute event rates are low: ischemic stroke 5.1 per 1,000 person-years in transfeminine patients versus 2.3 in cis women and 2.7 in cis men; MI 5.4 versus 2.7 and 5.0. Patients driving the signal were predominantly over 50, on long-term oral estrogen, often with hypertension and smoking history. Younger non-smoking transfeminine adults on transdermal estrogen do not show convincing arterial event elevations in any cohort to date, though those subgroups are small.
Mechanistic plausibility for stroke is stronger than for MI: estrogen-driven hypercoagulability plus age-related atrial fibrillation risk plausibly increases cardioembolic stroke, expected to track with oral exposure more than transdermal. MI risk drivers (atherosclerosis, plaque rupture) are less clearly modulated by estrogen and more clearly tied to traditional risk factors.
The Amsterdam ENIGI long-term picture¶
ENIGI is the most important single dataset for long-term cardiovascular outcomes in transfeminine adults — VU University Medical Center cohort begun 1972, expanded across the European Network for the Investigation of Gender Incongruence, with median follow-up of 9–10 years. Three caveats matter for interpretation:
- Era effects. A meaningful fraction of cumulative person-years comes from patients on ethinyl estradiol or high-dose oral conjugated estrogens — regimens no longer used. Sub-analyses restricted to post-2000 modern 17β-estradiol regimens show smaller VTE and stroke signals, though still elevated above cisgender-female baseline.
- Cohort age skew. Median follow-up extends into patients' 50s and early 60s; the bulk of person-years is in 30s and 40s. Outcomes for transfeminine adults on continuous HRT into their 70s and 80s are essentially absent from any prospective dataset.
- Smoking confounding. Older European transfeminine cohorts have substantially higher smoking prevalence than matched cisgender controls, and adjustment is imperfect. The Nota stroke signal is partially attenuated but not eliminated by smoking adjustment.
The ENIGI signal robust across all sub-analyses and eras: first-year VTE peak on oral estrogen, persistent modest VTE elevation thereafter, ischemic stroke elevation in older long-term users. Everything else is more uncertain. See The 5+ Year Trajectory for surrogate-marker trends over time.
Combining HRT with cardiovascular medications¶
| Drug class | HRT interaction |
|---|---|
| Statins | None clinically meaningful; rosuva-/atorvastatin preferred |
| ACE inhibitors / ARBs | No interaction; first-line for HTN |
| Thiazides | Combine cautiously with high-dose spironolactone (K+ monitoring) |
| Beta-blockers | No interaction |
| Amlodipine | No interaction |
| Diltiazem / verapamil | Weak CYP3A4 inhibition may modestly raise E2 |
| DOACs / warfarin | No specific interaction; transdermal often acceptable post-VTE |
| Aspirin / clopidogrel | No interaction |
| PCSK9 inhibitors | No interaction |
| Loop diuretics | Combine with high-dose spironolactone with electrolyte monitoring |
Spironolactone has cardiovascular effects beyond its anti-androgen role: it's a proven mortality-reducer in heart failure with reduced ejection fraction (RALES) at 25–50 mg/day. Patients who develop HFrEF on spironolactone may continue it for both indications.
Honest summary¶
Long-term feminizing HRT carries a real but bounded cardiovascular risk profile. The first-year VTE peak is the most robust finding and is largely modifiable by route. Long-term (5+ year) outcomes on modern transdermal-dominant regimens look favorable on lipids, neutral-to-favorable on BP, and modestly elevated for ischemic stroke in older long-term oral users. Most data come from cohorts skewing younger than 50; outcomes into the 70s on continuous HRT are genuinely uncertain.
The actionable hierarchy: don't smoke, switch to transdermal at 40 or earlier if any risk factor stacks, treat hypertension and lipids by standard guidelines, take statins when indicated without worrying about HRT interaction, monitor potassium on spironolactone, and don't reflexively stop HRT after a VTE — switch route and continue under hematology guidance.
Sources¶
- Nota NM, Wiepjes CM, de Blok CJM, et al. Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy. Circulation 2019;139:1461–1462.
- Getahun D, Nash R, Flanders WD, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study. Annals of Internal Medicine 2018;169:205–213.
- Wiepjes CM, Nota NM, de Blok CJM, et al. The Amsterdam Cohort of Gender Dysphoria Study (1972–2015): trends in prevalence, treatment, and regrets. Journal of Sexual Medicine 2018;15:582–590.
- Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2017;102:3869–3903.